CD8A and neoplasm: Analysis of 1041 early stage CRC from a mature clinical trial, showed that the combination of CD8+ T-lymphocyte fraction and stroma fraction can improve current prognostic-risk stratification methods, demonstrating the biological importance of the tumor microenvironment in determining outcome.